Thrombospondins in cancer.
Kazerounian, S, K O Yee, and J Lawler. 2008. “Thrombospondins in Cancer.”. Cellular and Molecular Life Sciences : CMLS 65 (5): 700-12.
Search
Search results
207 results found
Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.
Daniel, Christoph, Kathrin Schaub, Kerstin Amann, Jack Lawler, and Christian Hugo. 2007. “Thrombospondin-1 Is an Endogenous Activator of TGF-Beta in Experimental Diabetic Nephropathy in Vivo.”. Diabetes 56 (12): 2982-9.
Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model.
Zhang, Xuefeng, Caitlin Connolly, Mark Duquette, Jack Lawler, and Sareh Parangi. 2007. “Continuous Administration of the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein Improves the Potency of Therapy in an Orthotopic Human Pancreatic Cancer Model.”. Cancer Letters 247 (1): 143-9.
The structures of the thrombospondin-1 N-terminal domain and its complex with a synthetic pentameric heparin.
Tan, Kemin, Mark Duquette, Jin-huan Liu, Rongguang Zhang, Andrzej Joachimiak, Jia-huai Wang, and Jack Lawler. 2006. “The Structures of the Thrombospondin-1 N-Terminal Domain and Its Complex With a Synthetic Pentameric Heparin.”. Structure (London, England : 1993) 14 (1): 33-42.
Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Zhang, Xuefeng, Eric Galardi, Mark Duquette, Jack Lawler, and Sareh Parangi. 2005. “Antiangiogenic Treatment With Three Thrombospondin-1 Type 1 Repeats versus Gemcitabine in an Orthotopic Human Pancreatic Cancer Model.”. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 11 (15): 5622-30.
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
Shaked, Yuval, Francesco Bertolini, Shan Man, Michael S Rogers, Dave Cervi, Thomas Foutz, Kimberley Rawn, et al. 2005. “Genetic Heterogeneity of the Vasculogenic Phenotype Parallels Angiogenesis; Implications for Cellular Surrogate Marker Analysis of Antiangiogenesis.”. Cancer Cell 7 (1): 101-11.
Role of thrombospondin-1 in the autologous phase of an accelerated model of anti-glomerular basement membrane glomerulonephritis.
Hochegger, Kathrin, Sara Knight, Christian Hugo, Gert Mayer, Jack Lawler, Tanya N Mayadas, and Alexander R Rosenkranz. 2004. “Role of Thrombospondin-1 in the Autologous Phase of an Accelerated Model of Anti-Glomerular Basement Membrane Glomerulonephritis.”. Nephron. Experimental Nephrology 96 (2).
C-mannosylation and O-fucosylation of the thrombospondin type 1 module.
Hofsteenge, J, K G Huwiler, B Macek, D Hess, J Lawler, D F Mosher, and J Peter-Katalinic. 2001. “C-Mannosylation and O-Fucosylation of the Thrombospondin Type 1 Module.”. The Journal of Biological Chemistry 276 (9): 6485-98.
The C-terminal domain of thrombospondin-1 induces vascular smooth muscle cell chemotaxis.
Nesselroth, S M, A I Willis, S Fuse, E T Olson, J Lawler, B E Sumpio, and V Gahtan. 2001. “The C-Terminal Domain of Thrombospondin-1 Induces Vascular Smooth Muscle Cell Chemotaxis.”. Journal of Vascular Surgery 33 (3): 595-600.
Residues F16-G33 and A784-N823 within platelet thrombospondin-1 play a major role in binding human neutrophils: evaluation by two novel binding assays.
Majluf-Cruz, A, J M Manns, A B Uknis, X Yang, R W Colman, R B Harris, W Frazier, J Lawler, and R A DeLa Cadena. 2000. “Residues F16-G33 and A784-N823 Within Platelet Thrombospondin-1 Play a Major Role in Binding Human Neutrophils: Evaluation by Two Novel Binding Assays.”. The Journal of Laboratory and Clinical Medicine 136 (4): 292-302.